The U.S. Department of Health and Human Services (HHS) announced yesterday that it is making up to 442,000 doses of the Jynneos® vaccine available under an accelerated Phase of the National Vaccine Strategy (NVS) to combat the current monkeypox virus (MPXV) outbreak in the USA.
In light of the recent U.S. FDA Emergency Use Authorization and revised dosing guidelines from the Centers for Disease Control and Prevention, HHS doubled the number of doses available as initially anticipated.
Will Millions of Monkeypox Vaccines be Needed?
Universal Health Care Affects Childhood Vaccination Rates
Countries with greater progress toward UHC had smaller declines in childhood immunization coverage during COVID-19 pandemic
Multidose BCG Protects Against COVID-19 in At-Risk Individuals
Efficacy of 92 percent found among at-risk COVID-19-unvaccinated individuals with type 1 diabetes
First Lady Jill Biden Has COVID-19
First Lady has received two vaccines plus two boosters, and so far, her symptoms are mild
COVID-19 Risk for Dialysis Patients Tied to Antibody Response to Vaccine
During omicron, risk for SARS-CoV-2 infection dependent on antibody response to COVID-19 vaccine regardless of number of doses
Neurologic Complications Common in Children Hospitalized With COVID-19
Presence of a neurologic complex chronic condition associated with higher odds for neurologic complications
Dupilumab Studied in Patients Hospitalized for COVID-19
No difference seen between dupilumab and placebo groups in adverse events or primary outcome of ventilator-free survival at 28 days